Djordje S Popovic
Djordje S Popovic is an expert in Endocrinology at Klinički centar Vojvodine (Serbia). As of October 2026, ScienceLeadR ranks Djordje S Popovic in the top 1% of experts worldwide for Diabetes Mellitus and Glucose Metabolism Disorders, and in the top 1% of experts in Serbia for Body Weight. Djordje S Popovic has authored 154 publications, the most recent in 2026. SLR score: 472 (community average: 125). How the SLR is computed.
LeadR Profile
Endocrinology
Subspecialties: Pharmacy - Public Health - Cardiology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2007 - 2026
Number : 154
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Diabetic Foot: An Unmet Opportunity for the Novel Antidiabetic Agents? PMID 42904905 — foot, diabetic foot | Int J Low Extrem Wounds | 2026 | 0 |
| Losing Muscle or Restoring Physiology? Reframing the Incretin Therapy Sarcopenia Concern. PMID 42804080 — quality of life, physiology, muscles, body composition, drug therapy, obesity, incretins, diagnosis, weight loss, therapeutics, sarcopenia | Adv Ther | 2026 | 0 |
| New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus. PMID 42803913 — diabetes mellitus, glucagon-like peptide-1 receptor, insulin, obesity, weight loss, glucagon, therapeutics, islet amyloid polypeptide, glucagon-like peptides, diabetes mellitus, type 2 | Diabetes Ther | 2026 | 0 |
| Beyond insulin resistance: insights into the clinical utility of TyG and TG/HDL-C in hospitalized patients. PMID 42778844 — insulin resistance, insulin, hormones, triglycerides | Hormones (Athens) | 2026 | 0 |
| Cardiovascular risk assessment in adults with type 1 diabetes: A cross-sectional comparison of two prediction models. PMID 42745719 — diabetes mellitus, bias, biomedical research, risk assessment, diabetes mellitus, type 1 | Biomol Biomed | 2026 | 0 |
LeadR Networks
Main global connection map